Replagal Antibody Response Should Be Studied Postmarketing, Cmte. Says
Executive Summary
Concerns about antibody response to Transkaryotic Therapies' Replagal should be addressed in studies following accelerated approval, FDA's Endocrinologic & Metabolic Advisory Committee recommended Jan. 14
You may also be interested in...
TKT Replagal Surrogate Data Should Be Reworked For Accelerated Approval
Transkaryotic Therapeutics' Replagal histologic data should be reevaluated to determine whether they may satisfy a surrogate endpoint for accelerated approval in Fabry Disease, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Jan. 14
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011